Strategic transactions and agreements - Morphimmune - Narrative (Details) $ / shares in Units, $ in Thousands		12 Months Ended
	Oct. 02, 2023 USD ($) $ / shares shares	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($) $ / shares
Asset acquisitions
Exercise price | $ / shares			$ 10.00
In-process research and development		$ 152,344	$ 80,802
Morphimmune Inc
Asset acquisitions
Number of shares issuable | shares	8,835,710
Exchange ratio	0.3042
Options to purchase shares of common stock | shares	2,472,563
Exercise price | $ / shares	$ 1.29
Consideration paid	$ 87,953
Transaction costs	792
Common stock issued to Morphimmune shareholders	$ 72,453
IPO share price per share | $ / shares	$ 8.20
Contingent consideration related to the value of Morphimmune share-based awards	$ 14,708
In-process research and development			$ 80,800